CARB-X awards MicrobeDx and Talis funding for diagnostics

Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) awarded up to $3.5 million to MicrobeDx (Los Angeles, Calif.) and up to $8.6 million to Talis Biomedical Corp (Menlo Park, Calif.) to develop diagnostics to detect infections.

MicrobeDx is developing a system for rapid detection of antibiotic resistant bacteria in the urinary tract. MicrobeDx's diagnostic system utilizes a transformational ribosomal RNA-based assay on a microfluidic disc platform. The award comprises $900,000 up front and an additional $2.6 million in milestones...